Chronic lung disease evident on HRCT is prominent among adolescents with perinatally acquired HIV and is linked to small airway obstruction.

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.